Dishman Carbogen Amcis (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Dishman Carbogen Amcis Limited |
|||
|
Price: ₹236.15 (-0.53%) | ||
| 52 Week Low: ₹133.00 52 Week High: ₹307.98 |
|||
| Market Capital: 3,567.36 Crore (Smallcap) | |||
| Healthcare -> Biotechnology | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Dishman Carbogen Amcis Share Price Target For 2025
- 1.1.1: Dishman Carbogen Amcis Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Dishman Carbogen Amcis Share Price Target For 2026
- 1.2.1: Dishman Carbogen Amcis Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Dishman Carbogen Amcis Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Dishman Carbogen Amcis Brief Company Overview
- 4: Dishman Carbogen Amcis Financial Performance
- 4.0.1: Is Dishman Carbogen Amcis A Good Buy For Long Term?
Dishman Carbogen Amcis, a Small Cap company in the Biotechnology Industry has delivered 216.2% returns in 5-year showing 35.6% quarterly revenue growth, making it a potential Multibagger.
To predict the Dishman Carbogen Amcis's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Dishman Carbogen Amcis Share Price Target For 2025
The line chart displays the monthly closing prices of Dishman Carbogen Amcis with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Dishman Carbogen Amcis shares in 2025, see the table below.
Dishman Carbogen Amcis Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 268.2 (+13.57%) | Price Action: Feb 2024 High |
| 2025 Target 2 | 265.1 (+12.25%) | Price Action: 31 Dec 2024 Low |
| 2025 Target 1 | 262.4 (+11.11%) | Price Action: 09 Dec 2024 Low |
| Current Price | 236.15 | Dishman Carbogen Amcis's share price as of 23 Jan 2025 |
| Stop Loss 1 | 224.15 (-5.09%) | Price Action: 19 Apr 2024 High |
| Stop Loss 2 | 221.55 (-6.19%) | Price Action: 22 Apr 2024 Low |
| Stop Loss 3 | 219.05 (-7.25%) | Price Action: 26 Mar 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Dishman Carbogen Amcis is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹257.81 serves as the nearest technical reference point.
Historical Returns: 3-month: +21.68% | 6-month: +16.73% | 1-year: +21.88%
Dishman Carbogen Amcis Share Price Target For 2026
The line chart displays the monthly closing prices of Dishman Carbogen Amcis with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Dishman Carbogen Amcis shares in 2026, see the table below.
Dishman Carbogen Amcis Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 369.58 (+56.5%) | Price Action: Chart |
| 2026 Target 2 | 362.69 (+53.58%) | Fibonacci Extension Level 64.90% |
| 2026 Target 1 | 354.0 (+49.9%) | Fibonacci Extension Level 123.60% |
| Current Price | 236.15 | Dishman Carbogen Amcis's share price as of 23 Jan 2025 |
| Stop Loss 1 | 207.23 (-12.25%) | Price Action: Nov 2015 High |
| Stop Loss 2 | 205.0 (-13.2%) | Price Action: 12 Feb 2024 High |
| Stop Loss 3 | 202.55 (-14.23%) | Price Action: 08 Feb 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Dishman Carbogen Amcis is currently trading at 58.9% of its 52-week range (₹133 - ₹307.98).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +21.88% | 3-year: +21.1% | 5-year: +216.21%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Dishman Carbogen Amcis Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹236.15 | ||
| 2025 | ₹428.92 | +81.63% | ₹435.35 |
| 2026 | ₹584.37 | +36.24% | ₹593.14 |
| 2027 | ₹776.73 | +32.91% | ₹788.38 |
| 2028 | ₹951.76 | +22.53% | ₹966.04 |
| 2029 | ₹1,405.47 | +47.67% | ₹1,426.55 |
| 2030 | ₹1,761.21 | +25.31% | ₹1,787.63 |
| 2031 | ₹2,256.59 | +28.12% | ₹2,290.44 |
| 2032 | ₹2,949.12 | +30.68% | ₹2,993.36 |
| 2033 | ₹3,741.97 | +26.88% | ₹3,798.10 |
| 2034 | ₹4,565.41 | +22% | ₹4,633.89 |
| 2035 | ₹5,817.45 | +27.42% | ₹5,904.71 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Dishman Carbogen Amcis Brief Company Overview
Dishman Carbogen Amcis Limited: A Leading Pharmaceutical Contract Manufacturing and Research Company Since its inception in 1983, Dishman Carbogen Amcis Limited has established itself as a reputable provider of contract research and manufacturing services to the global...
pharmaceutical industry. The company offers a comprehensive suite of services, including bulk drug manufacturing, active pharmaceutical ingredients, and contract research. Their diverse product range encompasses generic and highly potent active pharmaceutical ingredients, vitamins, disinfectants, and cosmetic-related products. Dishman Carbogen Amcis Limited is committed to innovation and quality, demonstrated through its state-of-the-art facilities and stringent regulatory compliance. Its commitment to sustainability and corporate social responsibility has earned the company widespread recognition within the industry.Dishman Carbogen Amcis Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 3,567.36 Crore | Market valuation of Dishman Carbogen Amcis's shares. |
| Revenue (TTM) | 2,611.69 Crore | Total revenue generated by Dishman Carbogen Amcis over the past twelve months. |
| Net Income (TTM) | -174.03 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +10.26% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -6.67% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+35.6% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
43.69 | Company's total debt divided by total shareholder equity. |
| Total Debt | 2,506.92 Crore | Sum of Dishman Carbogen Amcis's current & long-term financial obligations. |
| Total Cash | 416.22 Crore | Total amount of liquid funds available to Dishman Carbogen Amcis. |
Is Dishman Carbogen Amcis A Good Buy For Long Term?
Dishman Carbogen Amcis (market cap: ₹3,567.36 crore) presents a mixed picture for long-term investors. While its revenue grew 35.6% QoQ (Q1 2024-25) and it boasts impressive 3-year (64.58%) and YTD (33.62%) returns, a substantial debt of ₹2,506.92 crore against a cash balance of ₹416.22 crore and a significant net loss of ₹174.03 crore (TTM) raise serious concerns. The negative profit margin (-6.67%) further highlights the risk. Therefore, it's currently a not a good buy for long-term investment, despite recent positive share price movements. Further investigation into the reasons behind the losses is crucial before considering investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
